Main characteristics of the study patients
| . | Thigh-length CES (n = 135) . | Below-knee CES (n = 132) . |
|---|---|---|
| Mean age, y (range) | 67 (20-94) | 69 (21-90) |
| Male sex, n (%) | 69 (51.1) | 73 (55.3) |
| Obesity, BMI > 30, n (%) | 26 (19.2) | 28 (21.2) |
| Thrombophilia in those tested, n (%) | 30/93 (32.3)* | 25/89 (28.1)† |
| Clinical presentation, n (%) | ||
| Unprovoked | 80 (59.3) | 82 (62.1) |
| Secondary | 55 (39.6) | 50 (37.9) |
| Risk factors, n (%) | ||
| Recent trauma or surgery | 22 (16.3) | 16 (12.1) |
| Malignancy | 12 (8.9) | 15 (11.4) |
| Medical diseases | 12 (8.9) | 14 (10.6) |
| Hormonal treatment | 7 (5.2) | 4 (3.0) |
| Pregnancy or puerperium | 2 (1.5) | 1 (0.8) |
| Location of DVT, n (%) | ||
| Popliteal only | 51 (37.8) | 64 (48.5) |
| Common femoral (with or without popliteal) | 84 (62.2) | 68 (51.5) |
| DVT treatment | ||
| LMWH/VKA, n (%)‡ | 124 (91.9) | 120 (90.9) |
| UFH/VKA, n (%) | 11 (8.1) | 12 (9.1) |
| VKA duration, mo (mean ± SD) | 10.3 ± 9.2 | 9.6 ± 8.6 |
| . | Thigh-length CES (n = 135) . | Below-knee CES (n = 132) . |
|---|---|---|
| Mean age, y (range) | 67 (20-94) | 69 (21-90) |
| Male sex, n (%) | 69 (51.1) | 73 (55.3) |
| Obesity, BMI > 30, n (%) | 26 (19.2) | 28 (21.2) |
| Thrombophilia in those tested, n (%) | 30/93 (32.3)* | 25/89 (28.1)† |
| Clinical presentation, n (%) | ||
| Unprovoked | 80 (59.3) | 82 (62.1) |
| Secondary | 55 (39.6) | 50 (37.9) |
| Risk factors, n (%) | ||
| Recent trauma or surgery | 22 (16.3) | 16 (12.1) |
| Malignancy | 12 (8.9) | 15 (11.4) |
| Medical diseases | 12 (8.9) | 14 (10.6) |
| Hormonal treatment | 7 (5.2) | 4 (3.0) |
| Pregnancy or puerperium | 2 (1.5) | 1 (0.8) |
| Location of DVT, n (%) | ||
| Popliteal only | 51 (37.8) | 64 (48.5) |
| Common femoral (with or without popliteal) | 84 (62.2) | 68 (51.5) |
| DVT treatment | ||
| LMWH/VKA, n (%)‡ | 124 (91.9) | 120 (90.9) |
| UFH/VKA, n (%) | 11 (8.1) | 12 (9.1) |
| VKA duration, mo (mean ± SD) | 10.3 ± 9.2 | 9.6 ± 8.6 |
LMWH indicates low-molecular-weight heparin; UFH, unfractionated heparin; and VKA, vitamin K antagonists.
FVL in 11 patients, PTM in 10, APL in 4, deficiency in AT in 2, deficiency in prot S in 1, and combined abnormalities in 2.
FVL in 11 patients, PTM in 7, APL in 4, and combined abnormalities in 3.
Eleven patients with cancer in each group were treated with LMWH monotherapy.